EMPOWERING DENDRITIC CELLS

Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer.
MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.

MEET US AT

19-22 March 2023
Bio Europe Spring – Basel

26-27 April 2023
Asia Bio Partnering Forum – Singapore